PMID- 17695395
OWN - NLM
STAT- MEDLINE
DCOM- 20070918
LR  - 20220330
IS  - 0022-3085 (Print)
IS  - 0022-3085 (Linking)
VI  - 107
IP  - 2
DP  - 2007 Aug
TI  - Treatment of traumatic brain injury in rats with erythropoietin and carbamylated 
      erythropoietin.
PG  - 392-7
AB  - OBJECT: This study was designed to investigate the neuroprotective properties of 
      recombinant erythropoietin (EPO) and carbamylated erythropoietin (CEPO) 
      administered following traumatic brain injury (TBI) in rats. METHODS: Sixty adult 
      male Wistar rats were injured with controlled cortical impact, and then EPO, 
      CEPO, or a placebo (phosphate-buffered saline) was injected intraperitoneally. 
      These injections were performed either 6 or 24 hours after TBI. To label newly 
      regenerating cells, bromodeoxyuridine was injected intraperitoneally for 14 days 
      after TBI. Blood samples were obtained on Days 1, 2, 3, 7, 14, and 35 to measure 
      hematocrit. Spatial learning was tested using the Morris water maze. All rats 
      were killed 35 days after TBI. Brain sections were immunostained as well as 
      processed for the enzyme-linked immunosorbent assay to measure brain-derived 
      neurotrophic factor (BDNF). RESULTS: A statistically significant improvement in 
      spatial learning was seen in rats treated with either EPO or CEPO 6 or 24 hours 
      after TBI (p < 0.05); there was no difference in the effects of EPO and CEPO. 
      Also, these drugs were equally effective in increasing the number of newly 
      proliferating cells within the dentate gyrus at both time points. A statistically 
      significant increase in BDNF expression was seen in animals treated with both EPO 
      derivatives at 6 or 24 hours after TBI. Systemic hematocrit was significantly 
      increased at 48 hours and 1 and 2 weeks after treatment with EPO but not with 
      CEPO. CONCLUSIONS: These data demonstrate that at the doses used, EPO and CEPO 
      are equally effective in enhancing spatial learning and promoting neural 
      plasticity after TBI.
FAU - Mahmood, Asim
AU  - Mahmood A
AD  - Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan 48202, 
      USA. nsaam@neuro.hfh.edu
FAU - Lu, Dunyue
AU  - Lu D
FAU - Qu, Changsheng
AU  - Qu C
FAU - Goussev, Anton
AU  - Goussev A
FAU - Zhang, Zheng Gang
AU  - Zhang ZG
FAU - Lu, Chang
AU  - Lu C
FAU - Chopp, Michael
AU  - Chopp M
LA  - eng
GR  - R01 NS042259/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Recombinant Proteins)
RN  - 0 (carbamylated erythropoietin)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Animals
MH  - Brain Injuries/*drug therapy/pathology/physiopathology
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Drug Administration Schedule
MH  - Erythropoietin/administration & dosage/*analogs & derivatives/*therapeutic use
MH  - Hematocrit
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Maze Learning/physiology
MH  - Neuronal Plasticity/physiology
MH  - Rats
MH  - Rats, Wistar
MH  - Recombinant Proteins
EDAT- 2007/08/19 09:00
MHDA- 2007/09/19 09:00
CRDT- 2007/08/19 09:00
PHST- 2007/08/19 09:00 [pubmed]
PHST- 2007/09/19 09:00 [medline]
PHST- 2007/08/19 09:00 [entrez]
AID - 10.3171/JNS-07/08/0392 [doi]
PST - ppublish
SO  - J Neurosurg. 2007 Aug;107(2):392-7. doi: 10.3171/JNS-07/08/0392.